Modelling therapy resistance in BRCA1/2 mutant cancers

Although PARP inhibitors target BRCA1 or BRCA2 mutant tumour cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or “revertant” mutations in BRCA1 or BRCA2. Whether secondary mutant tumour cells are selected for in a Darwinian fashion...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mol Cancer Ther
Prif Awduron: Dréan, Amy, Williamson, Chris T., Brough, Rachel, Brandsma, Inger, Menon, Malini, Konde, Asha, Garcia-Murillas, Isaac, Pemberton, Helen N., Frankum, Jessica, Rafiq, Rumana, Badham, Nick, Campbell, James, Gulati, Aditi, Turner, Nicholas C., Pettitt, Stephen J., Ashworth, Alan, Lord, Christopher J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6157714/
https://ncbi.nlm.nih.gov/pubmed/28619759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-17-0098
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg